Targeting Polo-like kinase 1 for treatment of NSCLC patients: focus on the induction of cellular senescence, the TP53 status and hypoxia. University of Antwerp
Center for Oncological Research (CORE), Molecular Imaging, Pathology, Radiotherapy & Oncology (MIPRO)
Non-small cell lung cancer (NSCLC), accounting for an estimated 85% of all lung cancers, retains its position as the most lethal type of cancer worldwide, with a 5-year survival rate for newly diagnosed cases below 20%. Despite the remarkable progress that has been made in the development of new treatment modalities, chemotherapy consisting of platinum-based doublets remains the standard first-line treatment for NSCLC patients. Anti-mitotic ...